TBRG4 as a prognostic biomarker and key regulator of cell cycle and EMT in lung cancer
Biomolecules and Biomedicine · 2025
DOI: 10.17305/bb.2025.11353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2025. Verfasst von Ansheng Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Epithelial-Mesenchymal Transition, Biomarkers, Tumor, Cell Cycle. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Transforming growth factor β regulator 4 (TBRG4) is upregulated in lung cancer, but its biological role and underlying mechanisms remain poorly understood. In this study, we analyzed pancancer gene expression profiles and clinical data from University of California, Santa Cruz Xena (UCSC Xena) to evaluate the prognostic significance of TBRG4 using univariate and multivariate Cox regression analyses. Genes with a Pearson correlation coefficient above 0.4 with TBRG4 in lung cancer were identified via UALCAN, followed by pathway enrichment analyses to explore their functional associations. To investigate TBRG4’s role in lung cancer progression, we assessed cell proliferation, colony formation, and cell cycle alterations in lung cancer cells following TBRG4 knockdown. Western blot analysis was performed to examine the effects of TBRG4 depletion on key cell cycle regulators and epithelial-mesenchymal transition (EMT) markers. Additionally, the biological significance of TBRG4 was evaluated in vivo using a mouse xenograft model. TBRG4 knockdown significantly inhibited cell proliferation and colony formation while inducing cell cycle arrest and apoptosis in lung cancer cells. Analysis of co-expressed genes in the The Cancer Genome Atlas - Lung Adenocarcinoma (TCGA-LUAD) cohort revealed enrichment in cell cycle-related pathways, aligning with our experimental findings. Furthermore, TBRG4 depletion reduced EMT marker expression and suppressed tumor growth in vivo. Collectively, these findings suggest that TBRG4 may serve as a promising prognostic biomarker and therapeutic target in lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
- Department of Anesthesia, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
- Department of Thoracic Surgery, Fuyang People's Hospital, Fuyang, Anhui, China.
Zitieren
APA
Wang, A., Ge, Q., Fan, Z., Xia, B., Jin, Z., Liu, H., Sang, H., Li, Q., Zhang, C., & Zhu, H. (2025). TBRG4 as a prognostic biomarker and key regulator of cell cycle and EMT in lung cancer. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2025.11353
Vancouver
Wang A, Ge Q, Fan Z, Xia B, Jin Z, Liu H, et al. TBRG4 as a prognostic biomarker and key regulator of cell cycle and EMT in lung cancer. Biomolecules and Biomedicine. 2025. doi:10.17305/bb.2025.11353
BibTeX
@article{Wang2025,
author = {Wang, Ansheng and Ge, Qiao and Fan, Zhenkai and Xia, Bing and Jin, Zhao and Liu, Haitao and Sang, Haiwei and Li, Qicai and Zhang, Congli and Zhu, Haonan},
title = {TBRG4 as a prognostic biomarker and key regulator of cell cycle and EMT in lung cancer},
journal = {Biomolecules and Biomedicine},
year = {2025},
doi = {10.17305/bb.2025.11353}
}
EUVIMED